Trastuzumab is a monoclonal antibody that targets the HER2 receptor and is mainly used in the treatment of HER2-positive breast cancers and HER2-positive cancers involving the gastroesophageal junction. This evidence concerns the gene ERBB2 and breast carcinoma.